Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer: A Phase 1b Clinical Trial

IMPORTANCE: The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in patients with estrogen receptor–positive (ER+), endocrine therapy–resistant breast cancers. OBJECTIVE: To assess the maximum tolerated dose (MTD), safety, and activity of alpelisib, an oral, PI3Kα-specific inhibi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Juric, Dejan, Janku, Filip, Rodón, Jordi, Burris, Howard A., Mayer, Ingrid A., Schuler, Martin, Seggewiss-Bernhardt, Ruth, Gil-Martin, Marta, Middleton, Mark R., Baselga, José, Bootle, Douglas, Demanse, David, Blumenstein, Lars, Schumacher, Karl, Huang, Alan, Quadt, Cornelia, Rugo, Hope S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2018
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439561/
https://ncbi.nlm.nih.gov/pubmed/30543347
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.4475
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados